Objective: To analyze the efficacy and safety of glimepiride made-in China in out-patients with T2DM. Methods: The T2DM out-patients whose blood glucoses were not well controlled were collected in 15 3rd grade first-class hospitals in Northern China, with the screening of questionnaires, physical examinations and laboratory examinations, and then glimepiride was recommended, reexamines were carried out 12 weeks later. The index of blood glucose before and after the treatment and possible influence factors were analyzed. Results: The levels of FBS, PBS and HbAlc were significantly improved after treatment, with the percentage of patients reaching HbAlc targets increasing greatly (20.29% vs 3.57%, P < 0.01) and less hypoglycemic events (0.06%), the hypoglycemic events happened in elderly were the same as that in the young patients. The coefficient correlation related with HbAlc range from high to low were FBS, duration and age. Conclusion: Switching to or adding glimepiride made-in China has high efficacy and safety on T2DM out-patients with unsatisfactory glucose control, including the elderly. Adding glimepiride to insulin resulted in well improvement of glycemic control. The levels of FBS, duration and age have relations with HbAlc after the treatment.%目的:研究国产格列美脲治疗门诊2型糖尿病患者的有效性和安全性.方法:华北地区15家三甲医院对门诊血糖控制欠佳的2型糖尿病患者进行问卷调查、查体和实验室检查,按推荐方式应用格列美脲,治疗12周时复测以上指标,分析治疗前后血糖指标和可能的影响因素.结果:治疗后患者的FBS、PBS和HbAlc均明显改善,HbAlc达标率显著提高(20.29％vs 3.57％,P＜0.01),低血糖事件发生率0.06％,老年人与青年人例数相当.HbAlc的相关系数由大到小依次为FBS、病程和年龄.结论:对于门诊血糖控制欠佳的2型糖尿病患者,换用或加用国产格列美脲后具有较好的疗效和安全性(包括老年人)；格列美脲可联合胰岛素治疗并获得较好的降糖效果；患者治疗后的HbAlc水平与FBS、病程和年龄有关.
展开▼
